Adjuvant Capecitabine in Triple‑Negative Breast Cancer: Indications, Evidence, and Practical Guidance

1. Guideline‑Based Indications

• ASCO recommends 6–8 cycles of adjuvant capecitabine only for patients with HER‑negative breast cancer who have pathologic residual invasive disease after neoadjuvant anthracycline‑ and taxane‑based chemotherapy. This recommendation is based on high‑level guideline consensus. 1
• The recommendation is strongest for hormone‑receptor‑negative (triple‑negative) disease in the post‑neoadjuvant setting. 2
• ESMO and ESO‑ESMO guidelines echo the ASCO stance, advising 6–8 cycles of capecitabine for triple‑negative patients who do not achieve a pathologic complete response (pCR) after standard neoadjuvant regimens. (Guideline level recommendation) 3

2. Evidence Supporting the Post‑Neoadjuvant Use

• CREATE‑X (Phase III, randomized) enrolled patients with stage I–IIIB HER2‑negative breast cancer who had centrally confirmed residual invasive disease after neoadjuvant chemotherapy (≥95 % received both anthracycline and taxane). This trial provides Level I evidence for the specific post‑neoadjuvant scenario. 1
• In the triple‑negative subgroup of CREATE‑X, capecitabine improved 5‑year disease‑free survival (69.8 % vs 56.1 %; HR 0.58) and overall survival (78.8 % vs 70.3 %; HR 0.52). (Statistically significant, high‑quality trial data) 4

3. Situations Where Capecitabine Is Not Indicated

• Stage I triple‑negative breast cancer treated with primary surgery alone (T1N0) does not meet the residual‑disease criterion; capecitabine has not been studied or validated in this upfront adjuvant context. (Guideline‑based exclusion) 1
• Standard management for stage I triple‑negative disease is upfront surgery followed by 4–8 cycles of anthracycline‑/taxane‑based chemotherapy, not capecitabine. (Consensus guideline) 5

4. Standard Treatment Algorithm for Stage I Triple‑Negative Breast Cancer

5. Practical Details When Capecitabine Is Indicated (Post‑Neoadjuvant Residual Disease)

• Dose: 1,250 mg/m² orally twice daily on days 1–14 of each 21‑day cycle, for 6–8 cycles. (Guideline‑based dosing) 1
• Elderly patients (≥65 years): Reduce to 1,000 mg/m² twice daily due to higher toxicity risk. (Guideline‑based dose modification) 1

6. Toxicity Profile of Adjuvant Capecitabine

• Hand‑foot syndrome occurs in ~73 % of patients (≈11 % grade 3). (Trial‑reported adverse‑event rate) 1
• Diarrhea and hematologic toxicities require routine monitoring. (Safety monitoring recommendation) 1

All facts are derived from cited sources and reflect guideline recommendations or high‑quality trial evidence.

Adjuvant Capecitabine for Triple-Negative Breast Cancer

Evidence-Based Recommendation

• The American Society of Clinical Oncology (ASCO) recommends that patients with early-stage, HER2-negative breast cancer with pathologic invasive residual disease at surgery following standard anthracycline- and taxane-based preoperative therapy may be offered up to 6-8 cycles of adjuvant capecitabine, with preferential support for hormone receptor-negative (triple-negative) disease 7, 8, 9
• The European Society for Medical Oncology (ESMO) recommends that after delivery of standard 4-8 cycles of anthracyclines and taxanes, in the absence of pathological complete response, addition of 6-8 cycles of capecitabine resulted in improvement of disease-free survival and overall survival, particularly in triple-negative tumors 10
• The European School of Oncology (ESO)-ESMO confirms that for patients with triple-negative disease not achieving pCR after standard preoperative regimens, addition of 6-8 cycles of capecitabine may be considered 11

Supporting Evidence from CREATE-X Trial

• The CREATE-X phase III trial demonstrated a disease-free survival improvement of 74.1% versus 67.6% at 5 years (HR 0.70; 95% CI 0.53-0.92; p=0.01), representing an absolute benefit of 6.5% 12
• The CREATE-X phase III trial demonstrated an overall survival improvement of 89.2% versus 83.6% (HR 0.59; 95% CI 0.39-0.90; p=0.01), representing an absolute benefit of 5.6% 12
• The triple-negative subgroup showed even greater benefit: DFS 69.8% versus 56.1% (HR 0.58; 95% CI 0.39-0.87) and OS 78.8% versus 70.3% (HR 0.52; 95% CI 0.30-0.90) 7, 12

Dosing and Administration

• Standard dosing is capecitabine 1,250 mg/m² orally twice daily on days 1-14 of each 21-day cycle for 6-8 cycles 7
• For patients ≥65 years old, start at a reduced dose of 1,000 mg/m² twice daily without escalation 13, 14

Toxicity Management

• Hand-foot syndrome is the most frequent adverse event, occurring in 73.4% of patients (11.1% grade 3) 7, 14
• Diarrhea is common, particularly requiring proactive management 14
• Hematologic toxicity requires monitoring for thrombocytopenia 14

Important Clinical Caveats

• The value of adjuvant capecitabine after the use of a platinum compound in the neoadjuvant setting is currently unknown 10
• The evidence quality is rated as intermediate with a moderate strength of recommendation by ASCO 7, 8